OVARIAN SEROMUCINOUS CARCINOMA

This study tested whether giving the chemotherapy drug paclitaxel weekly works better than the standard every-3-weeks schedule for people with advanced ovarian, peritoneal, or fallopian tube cancer. All participants also received carboplatin, and some received the targeted drug b…

This study tests whether combining three drugs (durvalumab, olaparib, and cediranib) works better than standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatment. About 120 participants will receive o…

This study looks at three different drug combinations for women with ovarian, fallopian tube, or primary peritoneal cancer that has returned and is no longer responding to platinum-based chemotherapy. The trial compares a standard chemotherapy drug (pegylated liposomal doxorubici…

This study tests a new treatment for ovarian cancer that has come back after standard therapy. It uses stem cells loaded with a modified measles virus to deliver cancer-killing effects directly into the abdomen. The trial involves 34 participants and aims to find the safest dose …

This study tested whether the targeted drugs olaparib (alone or with cediranib) work better than standard platinum-based chemo for women with ovarian, fallopian tube, or peritoneal cancer that came back after initial treatment. About 579 women with platinum-sensitive cancer took …

This study tests whether adding the experimental drug AZD1775 to standard chemotherapy (gemcitabine) helps women with ovarian, fallopian tube, or peritoneal cancer that has stopped responding to platinum-based treatments. About 124 participants will receive either the combination…

This study looked at whether combining two targeted drugs (cediranib and olaparib) works better than either drug alone or standard chemotherapy for women with ovarian, fallopian tube, or peritoneal cancer that came back or grew during platinum-based chemo. About 582 women took pa…

This early-phase trial tests a new drug (peposertib) combined with standard chemotherapy (PLD) in people with ovarian or related cancers that no longer respond to platinum-based treatment. The main goal is to find the safest dose and check for side effects. About 54 participants …

This study looked at whether adding the drug bevacizumab to standard chemotherapy after surgery helps people with ovarian, peritoneal, or fallopian tube cancer that has come back live longer. Over 1,000 participants were randomly assigned to receive chemo alone or chemo plus beva…